TEIPP peptide variant and use as a medicament

Patent metadata

Field	Value
Publication number	US-12534497-B2
Application number	US-202017780398-A
Country	US
Kind code	B2
Filing date	Nov 25, 2020
Priority date	Nov 29, 2019
Publication date	Jan 27, 2026
Grant date	Jan 27, 2026

Abstract

Novel nucleic acid sequences, vectors, cells, binding agents, peptides and pharmaceutical compositions are provided that are useful as a medicament, for example in the prevention or treatment of cancer or viral infections associated with impaired HLA class I antigen presentation. Corresponding methods and uses are also provided.

First claim

The invention claimed is:

1 . An isolated peptide, wherein the isolated peptide:
(a) consists of the amino acid sequence FLGPWPAAV (SEQ ID NO: 1); or (b) comprises the amino acid sequence FLGPWPAAV (SEQ ID NO: 1) and wherein the isolated peptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 3 to 8 and has no more than 35 amino acids.

2 . The peptide of claim 1 , wherein
the peptide consists of from 10 to 35 amino acids.

3 . The peptide of claim 1 , wherein the peptide is conjugated to a toll-like receptor (TLR) ligand.

4 . A cell loaded with a peptide according to claim 1 .

5 . The cell of claim 4 , wherein the cell is an antigen-presenting cell.

6 . The cell of claim 5 , wherein the antigen-presenting cell is selected from a macrophage, a dendritic cell, a monocyte, a B-cell or a synthetic form of an antigen presenting cell.

7 . A pharmaceutical composition comprising an isolated peptide according to claim 1 , and a pharmaceutically acceptable excipient, adjuvant, diluent and/or carrier.

8 . The pharmaceutical composition of claim 7 , wherein the composition is formulated as a vaccine.

9 . A pharmaceutical composition according to claim 7 for use as a medicament.

10 . The pharmaceutical composition for use according to claim 9 , in the prevention or treatment of a cancer or a viral infection associated with impaired HLA class I antigen presentation in a human subject.

11 . The pharmaceutical composition for use according to claim 10 , wherein the cancer is a cancer with impaired peptide processing machinery.

12 . A pharmaceutical composition according to claim 7 for use in treating or preventing a cancer or viral infection associated with impaired HLA class I antigen presentation in a human subject, wherein the subject has been identified as having a cancer or viral infection associated with impaired HLA class I antigen presentation by the presence of a peptide in a sample isolated from the subject, wherein the peptide is FLGPWPAAS (SEQ ID NO: 2).

Assignees

• Academisch Ziekenhuis Leiden

Inventors

• Van Hall Thorbald
• Van Der Burg Sjoerd Henricus
• Marjit Koen

Classifications

• C12N15/63

  Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title

• C07K16/28

  against receptors, cell surface antigens or cell surface determinants · CPC title

• C12N5/0645

  Macrophages, e.g. Kuepfer cells in the liver; Monocytes · CPC title

• C12N5/0639

  Dendritic cells, e.g. Langherhans cells in the epidermis · CPC title

• C12N5/0635

  B lymphocytes · CPC title